Deka Biosciences, Inc Announces Submission of Investigational New Drug (IND) Application for Lead Oncology Asset, DK210 (EGFR)

/PRNewswire/ -- Today, Deka Biosciences, Inc. (Deka), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory...

Related Keywords

John Mumm ,Deka Biosciences ,Deka Biosciences Inc ,Drug Administration ,Important Regulatory Milestone Provides Runway ,Investigational New Drug ,Health Care Amp Hospitals ,Medical Pharmaceuticals ,Biotechnology ,Pharmaceuticals ,Clinical Trials Amp Medical Discoveries ,New Products Amp Services ,